Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 7/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948957 | 0.84 | NOTUM (0.46) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL14575084 | 0.76 | ATAD2 (0.44) | MAPK1MEN1KMT2APDK1PDK2 | |
| SCHEMBL3457232 | 0.71 | ALDH1A1 (0.72) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL1994565 | 0.69 | NR1H2 (0.39) | ALDH1A1HTTNPC1RAB9AMEN1 | |
| SCHEMBL14321151 | 0.69 | PDK1 (0.39) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL22835563 | 0.69 | LMNA (0.37) | LMNA | |
| SCHEMBL1650576 | 0.69 | PDK1 (0.62) | NPC1RAB9AMEN1KMT2ATSHR | |
| SCHEMBL3456458 | 0.68 | MAPK1 (0.73) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL9655736 | 0.68 | MAPK1 (0.60) | MAPK1ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL7981548 | 0.67 | NOTUM (0.73) | ALDH1A1HTTNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1912989-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | MAPK1 2185/4885ALDH1A1 1887/4885HTT 1429/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | MAPK1 2185/4885ALDH1A1 1887/4885HTT 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.